Category - Developments

Developments

Study with Daxor BVA-100 published in Circulation

Blood volume outcome data has been published in the American Heart Association journal, Circulation, utilizing Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device to determine the primary endpoint...

May 22, 2020

Developments

Cidara doses first patient in Phase 3 rezafungin trial

Cidara Therapeutics (NASDAQ:CDTX) dosed the first patient in its Phase 3 trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation. The...

May 21, 2020

Developments

Passage Bio gets rare pediatric disease designation for gangliosidosis

Passage Bio’s (NASDAQ:PASG) PGBM01 received FDA rare pediatric disease designation for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a rare genetic disease where mutations in the GLB1 gene impair...

May 21, 2020

Developments

Kadmon reports positive topline results from pivotal GvHD trial

Kadmon Holdings (NYSE:KDMN) reported positive topline results from its pivotal trial of KD025 (belumosudil) in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of...

May 21, 2020

Developments

Imagin Medical receives functional i/Blue Imaging Systems

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) received functional i/Blue systems from its contract design and development firm, Optel, which will be used to conduct in...

May 21, 2020

Developments

Hepion advances to fourth dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the fourth dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 225 mg dosing level to be safe and...

May 20, 2020

Developments

Bee Vectoring in cranberry trials with natural pesticide

Bee Vectoring Technologies International (TSXV, CVE:BEE; OTCQB:BEVVF) plans to conduct trials of its natural precision agriculture system on cranberries in Massachusetts and New Jersey, two major cranberry growing...

May 20, 2020

Developments

Maxim ups Co-Diagnostics to buy; PT $30

Maxim Group upgraded Co-Diagnostics (NASDAQ:CODX) to “buy” from “hold” with a $30 price target, saying that COVID-19 testing has been transformative for the company. The stock closed at $18.85 on May 19. Co-Diagnostics...

May 20, 2020

Developments

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer. “Our system has been found to improve...

May 19, 2020

Developments

HalioDx to generate tumor immune contexture data for ImCheck Phase 1/2 trial

HalioDx, a closely-held immuno-oncology diagnostic company, signed a collaboration with ImCheck Therapeutics to generate tumor immune contexture information for patients enrolled in EVICTION, the first-in-human clinical...

May 19, 2020

Category - Developments

Study with Daxor BVA-100 published in Circulation

Cidara doses first patient in Phase 3 rezafungin trial

Passage Bio gets rare pediatric disease designation for gangliosidosis

Kadmon reports positive topline results from pivotal GvHD trial

Imagin Medical receives functional i/Blue Imaging Systems

Hepion advances to fourth dosing level in ongoing Phase 1 study of CRV431

Bee Vectoring in cranberry trials with natural pesticide

Maxim ups Co-Diagnostics to buy; PT $30

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

HalioDx to generate tumor immune contexture data for ImCheck Phase 1/2 trial

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter